Welcome to our dedicated page for 908 Devices news (Ticker: MASS), a resource for investors and traders seeking the latest updates and insights on 908 Devices stock.
News and updates for 908 Devices Inc. (NASDAQ: MASS) center on its development and deployment of purpose-built handheld devices for chemical analysis in health, safety and defense technology applications. The company reports that its tools are used at the point of need to interrogate unknown and invisible materials and provide quick, actionable answers in situations involving drugs, toxic chemicals and security threats.
Investors and observers following 908 Devices can expect regular news on quarterly financial results, including revenue from product sales, service and contract revenue, recurring revenue tied to its installed base, and non-GAAP measures such as adjusted gross margin and adjusted EBITDA. These updates are often accompanied by commentary on channel mix, recurring revenue trends and strategic focus on handheld chemical analysis tools.
The company also issues news about product developments and launches. Recent announcements describe handheld analyzers that combine FTIR and Raman spectroscopy through proprietary Smart Spectral Processing algorithms, as well as devices designed for rapid field-based identification of unknown bulk solids, liquids, gases and vapors. Such releases highlight capabilities like trace-level detection of drugs, explosives and hazardous materials, wireless connectivity and integration with the 908 Devices Team Leader app.
Another key theme in 908 Devices’ news flow is adoption by government and defense organizations. Public updates have detailed purchases of handheld mass spectrometry and gas identification devices by entities such as the United States Coast Guard and United States Marine Corps for narcotics interdiction, hazardous threat detection and protection of installations and coastal communities.
Corporate governance and investor relations activities also appear in the news stream, including participation in investor conferences, webcasts of earnings calls and changes to the Board of Directors that align with the company’s focus on public health, safety and defense tech. For a comprehensive view of how 908 Devices is executing its strategy, readers can review this evolving news record over time.
908 Devices (Nasdaq: MASS) reported a 17% increase in Q3 2024 revenue to $16.8 million, driven by newly acquired handheld products. However, challenges included the delayed FY24 federal budget, international contract delays, and softness in the bioprocessing and life science instrumentation market. Handheld revenue rose 19% to $14.0 million, while desktop revenue increased 8% to $2.8 million. Recurring revenue surged 70% to $6.1 million, making up 36% of total revenue. The company ended the quarter with $71.7 million in cash and no debt. Despite a net loss of $29.3 million and an adjusted EBITDA loss of $6.9 million, 908 Devices expects full-year 2024 revenue to range between $56 million and $58 million, a growth of 11%-15% over 2023. Structural changes include transitioning manufacturing to North Carolina and Connecticut, reducing operating expenses, and integrating the sales organization for efficiency.
908 Devices (Nasdaq: MASS), a company specializing in handheld and desktop chemical analysis devices, has announced its participation in two upcoming investor conferences. The company will participate in a fireside chat at the Stifel Healthcare Conference in New York on November 19 at 8:35 a.m. Eastern Time, and at the 26th Annual Stephens Investment Conference in Nashville on November 20 at 4 p.m. Eastern Time. Live and archived webcasts of both sessions will be available on the company's website investor section.
908 Devices Inc. (Nasdaq: MASS), a pioneer in handheld and desktop chemical analysis devices, has announced its plan to release third quarter 2024 financial results on Tuesday, November 12, 2024, before the market opens. The company will host a conference call and webcast at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on the same day to discuss the results.
Interested parties can access the live audio webcast on the "Investors" section of the company's website at www.908devices.com. For those unable to attend the live event, an archived version of the webcast will be made available for replay within 24 hours after the event concludes.
908 Devices (Nasdaq: MASS), known for its innovative handheld and desktop devices for chemical analysis, will participate in the virtual Craig-Hallum Bioprocessing Conference. The event takes place on September 19, beginning with a fireside chat hosted by the management at 10:15 a.m. Eastern Time. A replay of the webcast will be accessible on the company's website in the 'Investors' section at 908devices.com.
908 Devices Inc. (Nasdaq: MASS) reported Q2 2024 financial results, showing a 16% year-over-year revenue increase to $14.0 million. Highlights include:
- Handheld revenue up 26% to $11.1 million
- Desktop revenue down 9% to $2.9 million
- Recurring revenue up 33% to $5.3 million (38% of total revenue)
- Gross margin improved by 490 basis points to 53%
- Installed base grew to 3,067 devices
The company completed the commercial integration of RedWave Technology and reiterated its 2024 revenue outlook of $63.0-$65.0 million, representing 25-29% growth over 2023. Cash position remains strong at $77.4 million with no debt.
908 Devices, a leader in portable chemical analysis tools, announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The company's management will present on Tuesday, August 13 at 1:00 p.m. Eastern Time. This event offers an opportunity for investors and industry professionals to gain insights into 908 Devices' growth strategies and market position.
Interested parties can access a live and archived webcast of the presentation through the 'Investors' section of the company's website at 908devices.com. This presentation may provide valuable information about the company's recent developments, financial performance, and future outlook in the chemical analysis device market.
908 Devices Inc. (Nasdaq: MASS), a pioneer in handheld and desktop chemical analysis devices, has announced it will release its second quarter 2024 financial results before the market opens on Tuesday, August 6, 2024. The company management will host a conference call and webcast at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time on the same day to discuss the results. Investors can access the live audio webcast on the company's website at www.908devices.com. The webcast will be archived and available for replay within 24 hours after the event.
908 Devices (Nasdaq: MASS) has appointed Michele M. Leonhart, former Administrator of the U.S. Drug Enforcement Administration (DEA), to its Board of Directors.
Leonhart brings over 34 years of law enforcement experience, having held various high-responsibility roles in the DEA, including Administrator from 2010-2015. Her expertise spans global drug enforcement, intelligence, and regulatory operations.
Chairman Kevin Hrusovsky and CEO Kevin J. Knopp highlighted Leonhart's vast government knowledge and her recent role as Board Chair of D.A.R.E. America.
Leonhart's expertise is expected to bolster 908 Devices' capabilities in providing advanced chemical analysis tools for law enforcement.
908 Devices, a chemical analysis device company, has upgraded its XplorIR portable gas and vapor analyzer. This enhancement allows the device to identify and quantify nearly 5,000 airborne chemicals in seconds. The XplorIR, utilizing Fourier Transform Infrared (FTIR) spectroscopy, is aimed at aiding first responders like fire departments and HAZMAT teams in making swift, informed decisions regarding personal protective equipment and remediation efforts. The device offers continuous monitoring, updating chemical compositions every four seconds and ensuring accurate detection even in dynamic conditions. This update signifies a pivotal development in public safety technology.
908 Devices (Nasdaq: MASS), a leading developer of handheld and desktop devices for chemical and biochemical analysis, announced its participation in two upcoming investor conferences. The company will host a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas, on May 29 at 8:00 a.m. CT. Additionally, 908 Devices will present at the William Blair 44th Annual Growth Stock Conference in Chicago, Illinois, on June 4 at 10:40 a.m. CT. Live and archived webcasts of these events will be available on their website.